Mouse anti-Human BHLHE40 polyclonal antibody

Significance analysis of proteomic data generated by LC-MS/MS is challenging owing to great data variability originated from biological, operational, and instrumental variations. Protein quantification by LC-MS/MS either in absolute or relative scale is often highly skewed, which put limitations on model-based statistical inference. For this purpose, we have developed an alternative nonparametric statistical algorithm (named IQR algorithm) for significance analysis of temporal proteomic data and have successfully applied our strategy in finding gefitinib-targeted transcription factors and coregulators in Epidermal Growth Factor (EGF)-stimulated HeLa cells. Our strategy relies on a reference group composed of more than a dozen of datasets collected at different experimental times, thus, accurately captures biological variations measured in quartile scale. The algorithm considers six categories and calculates signal strength when performing significance analysis of proteins of different abundances. This stratified strategy allows confident identification of well-characterized EGF responders (e.g. EGR1, JUN, FOSB, BHLHE40, NR4A1, and NR4A2) and unexplored gefitinib induced transcription factors and coregulators in HeLa cells. Gene set enrichment analysis has validated ErbB signaling pathway as the major inhibitory target of gefitinib. The identification of several gefitinib-inducible transcription factors implicates alternative signaling pathways as potential druggable pathways in gefitinib-resistant or insensitive patients.

Basic helix-loop-helix family member e40 (BHLHE40) is located in 3p26.1 and acts as a transcriptional repressor of the circadian rhythm by suppressing the expression of the clock genes and clock-controlled genes. Recent research indicated that BHLHE40 may be involved in regulating tumor cell progression. However the mechanism by which BHLHE40 regulates the invasion and metastasis of tumor cells is unclear. Our in vitro assays showed that BHLHE40 promoted tumor cell invasion while BHLHE40 silencing by siRNA suppressed tumor cell invasion of MCF-7 cells. BHLHE40 suppressed the mRNA and protein expression of CLDN1 CLDN4 and CDH1 and promoted the expression of SNAI1 and SNAI2. Reporter assays demonstrated that BHLHE40 suppressed CLDN1 transcription but not through direct binding to the E-box motifs in the CLDN1 promoter. Further studies demonstrated BHLHE40 suppressed CLDN1 transcription by preventing the interaction between SP1 and a specific motif within the promoter region of CLDN1. BHLHE40 could not further suppress CLDN1 transactivation after SP1 siRNA transfection that is, BHLHE40-induced suppression of CLDN1 relied on SP1. Furthermore our data indicated that SP1 was a major regulator of CLDN1 transcription by binding to a specific motif that was located at -233 to -61bp upstream of the transcription start site. Immunoprecipitation and co-localization data revealed an interaction between BHLHE40 and SP1. By constructing deletion mutants we found that the BHLH and Orange regions are both essential for the BHLHE40-SP1 interaction. BHLHE40 probably acts as an inhibitory nuclear cofactor or perhaps recruits other inhibitory cofactors to inhibit the SP1-mediated CLDN1 transactivation. These results suggest that BHLHE40 facilitates cell invasion and may be used as a novel target for breast cancer prevention and treatment.